Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20268 Citations
Beginner, moderate, and aggressive dosing amounts with timing. Free, no signup.
Subcutaneous
Pemvidutide (ALT-801) has no standard bacteriostatic water volume on file, so there are no syringe units to calculate here. Dosing runs 1.2mg to 2.4mg per administration, weekly. A 5mg supply covers about 4 doses at the beginner tier.
If your product does arrive as a powder, use the universal reconstitution calculator and enter your own vial size and water volume.
Pemvidutide (ALT-801) combines GLP-1 and glucagon receptor activation in a single weekly injection. Phase 2 data: 15.6% weight loss plus up to 76% liver fat reduction. FDA Breakthrough Therapy Designation for MASH granted January 2026. Currently, clinical trial access only.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1.2mg | Weekly |
| Moderate | 1.8mg | Weekly |
| Aggressive | 2.4mg | Weekly |
Pemvidutide isn't available from any consumer or grey-market source. The EuPort lipidated/albumin-conjugated structure can't be synthesized by research peptide vendors. Any product claiming to be pemvidutide from a peptide supplier is mislabeled or outright fraudulent. In clinical trials, pre-filled pens were used, so reconstitution wasn't part of the protocol. If you encounter research-grade lyophilized material (MedChemExpress catalog HY-P99852, preclinical use only), reconstitution math for reference: a 5 mg vial plus 2 mL bacteriostatic water gives 2.5 mg/mL. At that concentration, 1.2 mg equals 48 units on a U-100 insulin syringe, 1.8 mg equals 72 units, and 2.4 mg equals 96 units. A 10 mg vial plus 2 mL gives 5 mg/mL, so the same doses become 24, 36, and 48 units respectively. The non-obvious point: no dose titration was mandated in MOMENTUM. But starting at 1.2 mg for four weeks before escalation is practical given the 52% nausea rate at the top dose. The 2.4 mg arm in MOMENTUM actually did use a four-week 1.2 mg lead-in.
Dosing based on Phase 2 trial: pemvidutide in adults with obesity (2024) — 11 published references.View all sources →
Cross-check your Pemvidutide (ALT-801) reconstitution math with AI
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.